RCUS Arcus Biosciences, Inc.

NYSE
$17.69

Arcus Biosciences, Inc. (RCUS) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.88 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.3% since its last earnings release on November 4, 2026.

Arcus Biosciences Missed Consensus Estimates, Narrows Guidance
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.88)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $17.69

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.

Sector

Healthcare

Industry

Biotechnology

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.